MIFH
ARQT icon

Migdal Insurance & Financial Holdings’s Arcutis Biotherapeutics ARQT Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-263
Closed -$5K – 605
2021
Q4 		$5K Sell
263
-158
-38% -$3.15K ﹤0.01% 644
2021
Q3 		$10K Buy
+421
New +$9.6K ﹤0.01% 594

Other funds holding ARQT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Migdal Insurance & Financial Holdings's ARQT Position: Q1 2022 in Review

Migdal Insurance & Financial Holdings sold out of Arcutis Biotherapeutics (ARQT) in Q1 2022, closing a stake of 263 shares — an estimated $5K sold.

Migdal Insurance & Financial Holdings first reported a position in ARQT in Q3 2021 and held it in 2 quarters. The position peaked at $10K in Q3 2021. 106 funds tracked by Wall St. Rank hold ARQT as of Q1 2022.

  • Migdal Insurance & Financial Holdings reported no remaining Arcutis Biotherapeutics position as of Q1 2022 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 263 Arcutis Biotherapeutics shares in Q1 2022, an estimated $5K.
  • Migdal Insurance & Financial Holdings first reported a position in Arcutis Biotherapeutics in Q3 2021 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's Arcutis Biotherapeutics position peaked at $10K in Q3 2021.
  • 106 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2022.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q1 2022, filed 2 May 2022.